|  |  | IFN-γ (fold change)a |  |
|---|
Antigens | Swine No. | rVP1 | PHA | Clinical symptomsb |
|---|
10 mg BVP1 | 858 | 3.8 | 2.4 | No |
| Â | 859 | 4.1 | 2.8 | No |
| Â | 860 | 3.4 | 2.2 | No |
5 mg BVP1 | 861 | 3.1 | 2.9 | No |
| Â | 862 | 3.8 | 2.1 | No |
| Â | 863 | 2.4 | 2.6 | No |
5 mg BaMV-S | 864 | 1.0 | 2.5 | Yes |
| Â | 865 | 1.1 | 2.2 | Yes |
PBS | 866 | 1.0 | 2.6 | Yes |
| Â | 867 | 1.0 | 2.4 | Yes |
- a PBMCs isolated from swine 10 weeks after priming were stimulated with 5 μg/ml of rVP1 or 1 μg/ml of PHA for 6 h at 37°C. Total cellular RNA was then extracted for the assay of IFN-γ production by real-time PCR. The fold change was determined by dividing the quantity of specific IFN-γ mRNA from stimulated cells by the quantity of IFN-γ mRNA from the unstimulated cells.
- b Swine of all groups were challenged with FMDV (O/Taiwan/97) and monitored daily for clinical symptoms of FMD for 14 days as described in Methods.
